Metastatic Castration-Resistant Prostate Cancer: Critical Review of Enzalutamide

Enzalutamide, previously known as MDV300, is an oral, second-generation androgen receptor (AR) signaling inhibitor or antagonist that was approved by the Food and Drug Administration in 2012 for the treatment of metastatic castrate-resistant prostate cancer (mCRPC) postdocetaxel. Preclinical studies...

Descripción completa

Detalles Bibliográficos
Autores principales: El-Amm, Joelle, Patel, Nihar, Freeman, Ashley, Aragon-Ching, Jeanny B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Libertas Academica 2013
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3813614/
https://www.ncbi.nlm.nih.gov/pubmed/24179414
http://dx.doi.org/10.4137/CMO.S11670

Ejemplares similares

Ejemplares similares